摘要
目的探讨宁泌泰胶囊联合前列安栓治疗合并性功能障碍Ⅲ型前列腺炎的临床疗效及预后的影响。方法纳入我院2018年8月—2019年6月的慢性前列腺炎合并性功能障碍患者共90例,对照组45例采用前列安栓治疗,观察组45例采用宁泌泰胶囊联合前列安栓治疗,两组患者各治疗4周。观察患者的临床疗效,检测患者的肿瘤坏死因子(tumor necrosis factor,TNF-α)、白介素-2(interleukin-2,IL-2)和IL-10、巨噬细胞集落刺激因子(macrophage colonystimulating factor,M-CSF),观察患者6个月的复发情况。结果对照组治疗的有效率为77.78%,观察组治疗的有效率为93.33%,观察组治疗有效率显著高于对照组(P<0.05)。治疗后两组患者的TNF-α较治疗前出现升高,IL-2、IL-10和M-CSF水平较治疗前出现下降(P<0.05);观察组治疗后的TNF-α较对照组显著升高,IL-2、IL-10和M-CSF水平出现显著下降(P<0.05)。对照组和观察组复发人数分别为9例(20.00%)和2例(4.44%),观察组复发率显著低于对照组(P<0.05)。结论宁泌泰胶囊联合前列安栓治疗合并性功能障碍Ⅲ型前列腺炎的临床疗效出现显著提高,改善了炎症因子指标,对患者的预后情况具有显著提高。
Objective To explore the clinical efficacy and prognosis of Ningbitai Capsule combined with Qianlie'an Suppository in the treatment of type III prostatitis with sexual dysfunction.Methods A total of 90 patients with chronic prostate complicated with sexual dysfunction were included in our hospital from August 2018 to June 2019.45 patients in the control group were treated with Qianliean Suppository,and 45 patients in the observation group were treated with Ningbitai capsules combined with Qianliean Suppository.Each group of patients was treated for 4 weeks.Observe the clinical efficacy of patients,detect tumor necrosis factor(TNF-α),interleukin-2(IL-2)and IL-10,macrophage colony-stimulating factor(M-CSF),and observe the patients'6-month relapse.Results The effective rate of treatment in the control group was 77.78%,and the effective rate of treatment in the observation group was 93.33%.The effective rate of treatment in the observation group was significantly higher than that in the control group(P<0.05).After treatment,the levels of TNF-α in the two groups were higher than before treatment,and the levels of IL-2,IL-10 and M-CSF were lower than before treatment(P<0.05);TNF-αin the observation group was lower than that in the control group.Significantly increased,and the levels of IL-2,IL-10 and M-CSF decreased significantly(P<0.05).The number of relapses in the control group and the observation group was 9(20.00%)and 2(4.44%),respectively.The recurrence rate in the observation group was significantly lower than that in the control group(P<0.05).Conclusion The clinical efficacy of Ningbitai Capsule combined with Qianlie'an Suppository in the treatment of patients with sexual dysfunction type III prostatitis has significantly improved,the indicators of inflammatory factors have been improved,and the prognosis of patients has been significantly improved.
作者
赖刘娟
何小玲
LAI Liujuan;HE Xiaoling(Department of Central Pharmacy,Xinyi Second People's Hospital,Xinyi Guangdong 525324,China;Department of Central Pharmacy,Zhenlong Medical Center of Xinyi City,Xinyi Guangdong 525347,China)
出处
《中国卫生标准管理》
2020年第14期117-120,共4页
China Health Standard Management
关键词
慢性前列腺炎
性功能障碍
宁泌泰胶囊
前列安栓
临床疗效
预后情况
chronic prostatitis
sexual dysfunction
Ningbitai capsule
Qianliean suppository
clinical efficacy
prognosis
